Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials
- PMID: 35599448
- PMCID: PMC9542331
- DOI: 10.1111/bjd.21236
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials
Abstract
Background: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials.
Objectives: To develop a novel HS Investigator Global Assessment (HS-IGA) and to validate its psychometric properties.
Methods: Development of HS-IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test-retest reliability, predictive validity, responsiveness and clinical meaningfulness.
Results: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS-IGA score. Accordingly, regions were combined into a six-point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0-1 lesions), 1 (2-5), 2 (6-10), 3 (11-15), 4 (16-20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test-retest reliability was 0·91 (95% confidence interval 0·87-0·94). Spearman's rank order correlations (SROCs) with HS-PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS-QoL were 0·42, 0·34 and -0·25, respectively (P < 0·001 for all comparisons). HS-IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS-PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS-QoL.
Conclusions: HS-IGA has moderate-to-strong psychometric properties and is simple to calculate.
© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Figures


Similar articles
-
Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.Front Med (Lausanne). 2023 Apr 17;10:1145152. doi: 10.3389/fmed.2023.1145152. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37138732 Free PMC article. Review.
-
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.JAMA Dermatol. 2023 Jun 1;159(6):606-612. doi: 10.1001/jamadermatol.2023.0797. JAMA Dermatol. 2023. PMID: 37099284 Free PMC article.
-
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11. Br J Dermatol. 2014. PMID: 25040429 Clinical Trial.
-
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110. Acta Dermatovenerol Croat. 2021. PMID: 34477078
-
New treatments and new assessment instruments for Hidradenitis suppurativa.Exp Dermatol. 2022 Sep;31 Suppl 1(Suppl 1):33-39. doi: 10.1111/exd.14609. Exp Dermatol. 2022. PMID: 35582833 Free PMC article. Review.
Cited by
-
Review of Scoring Systems for Hidradenitis Suppurativa.Ann Dermatol. 2024 Feb;36(1):9-17. doi: 10.5021/ad.23.090. Ann Dermatol. 2024. Retraction in: Ann Dermatol. 2024 Aug;36(4):255. doi: 10.5021/ad.36.001. PMID: 38325429 Free PMC article. Retracted. Review.
-
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19. J Eur Acad Dermatol Venereol. 2025. PMID: 39699926 Free PMC article.
-
Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.Front Med (Lausanne). 2023 Apr 17;10:1145152. doi: 10.3389/fmed.2023.1145152. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37138732 Free PMC article. Review.
-
Evaluation of eating behaviors in patients with hidradenitis suppurativa: A case-control study.Arch Dermatol Res. 2025 Feb 14;317(1):408. doi: 10.1007/s00403-025-03919-3. Arch Dermatol Res. 2025. PMID: 39951135
References
-
- Garg A, Lavian J, Lin G et al. Incidence of hidradenitis suppurativa in the United States: a sex‐ and age‐adjusted population analysis. J Am Acad Dermatol 2017; 77:118–22. - PubMed
-
- Garg A, Neuren E, Cha D et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) project. J Am Acad Dermatol 2020; 82:366–76. - PubMed
-
- Reddy S, Strunk A, Garg A. All‐cause mortality among patients with hidradenitis suppurativa: a population‐based cohort study in the United States. J Am Acad Dermatol 2019; 81:937–42. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous